⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24711284 | 0.76 | — | — | |
| SCHEMBL9749123 | 0.76 | — | — | |
| SCHEMBL20961930 | 0.74 | — | — | |
| SCHEMBL995245 | 0.72 | MEN1 (0.39) | — | |
| SCHEMBL26318922 | 0.70 | DNM1 (0.39) | — | |
| SCHEMBL8632146 | 0.67 | — | — | |
| SCHEMBL7570930 | 0.67 | MEN1 (0.35) | — | |
| Vpn-4090Ce SCHEMBL259901 | 0.64 | MEN1 (0.32) | — | |
| SCHEMBL1075527 | 0.63 | LMNA (0.32) | — | |
| Methylene Chloride SCHEMBL18529805 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102210698-A | Use of composition containing 3-aminopyridine-2-formaldehyde thiosemicarbazone in treatment of cancers | VION PHARMACEUTICALS INC | 2011-10-12 | — | — | CN | disclosed |
| EP-1804816-A4 | COMBINATION THERAPY COMPRISING CLORETAZINE(TM) | VION PHARMACEUTICALS INC (US) | 2009-07-01 | — | — | EP | disclosed |
| CN-100427139-C | Water-soluble shps as novel alkylating agents | VION PHARMACEUTICALS INC (US) | 2008-10-22 | — | — | CN | disclosed |
| CN-101014353-A | Combination therapy comprising cloretazine(tm) | VION PHARMACEUTICALS INC (US) | 2007-08-08 | — | — | CN | disclosed |
| EP-1804816-A2 | COMBINATION THERAPY COMPRISING CLORETAZINE(TM) | Vion Pharmaceuticals, Inc. (US) | 2007-07-11 | — | — | EP | disclosed |
| CN-1805752-A | Water-soluble shps as novel alkylating agents | VION PHARMACEUTICALS INC (US) | 2006-07-19 | — | — | CN | disclosed |
| WO-2005094282-A2 | COMBINATION THERAPY COMPRISING CLORETAZINETM | VION PHARMACEUTICALS, INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| CN-1555798-A | Cancer treatment comprising 3-aminopyridine-2-carboxaldehyde thiosemicarbazone | 维奥恩药品公司 | 2004-12-22 | — | — | CN | disclosed |
| CN-1176067-C | Anti-tumor 2-amino-carboyl-1,2-di (methylsulfonyl)-1-(substituted) diazane | Ү³��ѧ | 2004-11-17 | — | — | CN | disclosed |
| CN-1124846-C | N, N' -bis (sulfonyl) hydrazines as antitumor agents | UNIV YALE (US) | 2003-10-22 | — | — | CN | disclosed |
| CN-1405152-A | Anti-tumor 2-amino-carboyl-1,2-di (methylsulfonyl)-1-(substituted) diazane | UNIV YALE (US) | 2003-03-26 | — | — | CN | disclosed |
| CN-1095828-C | Antitumor 2-aminocarbonyl-1, 2-bis (methylsulfonyl) -1- (substituted) hydrazines | UNIV YALE (US) | 2002-12-11 | — | — | CN | disclosed |
| CN-1278169-A | N, N' -bis (sulfonyl) hydrazines as antitumor agents | UNIV YALE (US) | 2000-12-27 | — | — | CN | disclosed |
| CN-1191482-A | Antitumor 2-aminocarbonyl-1, 2-bis (methylsulfonyl) -1- (substituted) hydrazines | UNIV YALE (US) | 1998-08-26 | — | — | CN | disclosed |
| EP-0541322-A1 | 1-Alkyl-2-acyl-1,2-disulfonylhydrazines with antineoplastic activity | YALE UNIVERSITY (US) | 1993-05-12 | — | — | EP | disclosed |